Clinical Applications of PET Imaging in Alzheimer's Disease

Shiv Patil; Cyrus Ayubcha; Eric Teichner; Robert Subtirelu; Julia H. Cho; Mohanad Ghonim; Mohamed Ghonim; Thomas J. Werner; Poul Flemming Høilund-Carlsen; Abass Alavi; Andrew B. Newberg

doi:10.1016/j.cpet.2024.09.015

Clinical Applications of PET Imaging in Alzheimer's Disease

Shiv Patil, Cyrus Ayubcha, Eric Teichner, Robert Subtirelu, Julia H. Cho, Mohanad Ghonim, Mohamed Ghonim, Thomas J. Werner, Poul Flemming Høilund-Carlsen, Abass Alavi, Andrew B. Newberg^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Alzheimer's disease (AD) involves a complex pathophysiology of neurodegeneration that leads to severe cognitive deficiencies. Understanding the molecular alterations that underlie this disease is fundamental to clinical management and therapeutic innovation. Functional imaging with positron emission tomography (PET) enables a visualization of these impaired pathways, such as cerebral hypometabolism, amyloid and tau accumulation, and neurotransmitter dysfunction. This review discusses the clinical applications of PET in AD and mild cognitive impairment, focusing on relevant original research studies for disease diagnosis, progression, and treatment response.

Originalsprog	Engelsk
Tidsskrift	PET Clinics
Vol/bind	20
Udgave nummer	1
Sider (fra-til)	89-100
ISSN	1556-8598
DOI	https://doi.org/10.1016/j.cpet.2024.09.015
Status	Udgivet - jan. 2025

Dokumenter og links

10.1016/j.cpet.2024.09.015

Citationsformater

@article{3842a79068e74db3816670b0b9af7d0e,

title = "Clinical Applications of PET Imaging in Alzheimer's Disease",

abstract = "Alzheimer's disease (AD) involves a complex pathophysiology of neurodegeneration that leads to severe cognitive deficiencies. Understanding the molecular alterations that underlie this disease is fundamental to clinical management and therapeutic innovation. Functional imaging with positron emission tomography (PET) enables a visualization of these impaired pathways, such as cerebral hypometabolism, amyloid and tau accumulation, and neurotransmitter dysfunction. This review discusses the clinical applications of PET in AD and mild cognitive impairment, focusing on relevant original research studies for disease diagnosis, progression, and treatment response.",

keywords = "Alzheimer's disease, Amyloid, Mild cognitive impairment, Positron emission tomography, Brain/diagnostic imaging, Humans, Alzheimer Disease/diagnostic imaging, Cognitive Dysfunction/diagnostic imaging, Radiopharmaceuticals, Positron-Emission Tomography/methods",

author = "Shiv Patil and Cyrus Ayubcha and Eric Teichner and Robert Subtirelu and Cho, {Julia H.} and Mohanad Ghonim and Mohamed Ghonim and Werner, {Thomas J.} and H{\o}ilund-Carlsen, {Poul Flemming} and Abass Alavi and Newberg, {Andrew B.}",

year = "2025",

month = jan,

doi = "10.1016/j.cpet.2024.09.015",

language = "English",

volume = "20",

pages = "89--100",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Clinical Applications of PET Imaging in Alzheimer's Disease

AU - Patil, Shiv

AU - Ayubcha, Cyrus

AU - Teichner, Eric

AU - Subtirelu, Robert

AU - Cho, Julia H.

AU - Ghonim, Mohanad

AU - Ghonim, Mohamed

AU - Werner, Thomas J.

AU - Høilund-Carlsen, Poul Flemming

AU - Alavi, Abass

AU - Newberg, Andrew B.

PY - 2025/1

Y1 - 2025/1

N2 - Alzheimer's disease (AD) involves a complex pathophysiology of neurodegeneration that leads to severe cognitive deficiencies. Understanding the molecular alterations that underlie this disease is fundamental to clinical management and therapeutic innovation. Functional imaging with positron emission tomography (PET) enables a visualization of these impaired pathways, such as cerebral hypometabolism, amyloid and tau accumulation, and neurotransmitter dysfunction. This review discusses the clinical applications of PET in AD and mild cognitive impairment, focusing on relevant original research studies for disease diagnosis, progression, and treatment response.

AB - Alzheimer's disease (AD) involves a complex pathophysiology of neurodegeneration that leads to severe cognitive deficiencies. Understanding the molecular alterations that underlie this disease is fundamental to clinical management and therapeutic innovation. Functional imaging with positron emission tomography (PET) enables a visualization of these impaired pathways, such as cerebral hypometabolism, amyloid and tau accumulation, and neurotransmitter dysfunction. This review discusses the clinical applications of PET in AD and mild cognitive impairment, focusing on relevant original research studies for disease diagnosis, progression, and treatment response.

KW - Alzheimer's disease

KW - Amyloid

KW - Mild cognitive impairment

KW - Positron emission tomography

KW - Brain/diagnostic imaging

KW - Humans

KW - Alzheimer Disease/diagnostic imaging

KW - Cognitive Dysfunction/diagnostic imaging

KW - Radiopharmaceuticals

KW - Positron-Emission Tomography/methods

U2 - 10.1016/j.cpet.2024.09.015

DO - 10.1016/j.cpet.2024.09.015

M3 - Journal article

C2 - 39547733

AN - SCOPUS:85208761167

SN - 1556-8598

VL - 20

SP - 89

EP - 100

JO - PET Clinics

JF - PET Clinics

IS - 1

ER -

Clinical Applications of PET Imaging in Alzheimer's Disease

Abstract

Dokumenter og links

Fingeraftryk

Citationsformater